Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions: Drug: low dose 5'-azacitidine

First Posted Date: 2013-11-26

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT01995578

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent and Follow-up), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent and Follow-up), Harrison, New York, United States

and more 4 locations

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Other: Standard of care
Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)

First Posted Date: 2013-11-26

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT01995708

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumor (GIST)

Interventions: Drug: MEK162
Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
Other: Blood draws
Procedure: biopsy

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT01991379

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Pre-test Assessment
Behavioral: Pre test Counseling
Other: Blood draw
Behavioral: Post-test counseling, and post-test assessment
Behavioral: Follow-up assessments (6 and 12 months)

First Posted Date: 2013-11-25

Last Posted Date: 2017-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 197

Registration Number: NCT01992471

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Behavioral: The risk assessment questionnaire
Other: Blood specimens
Other: tumor tissue samples will be requested

First Posted Date: 2013-11-14

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 600

Registration Number: NCT01983410

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 10 locations

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Phase 2

Completed

Conditions: Advanced Epithelial Ovarian
Primary Peritoneal Carcinoma
Recurrent Epithelial Ovarian
Fallopian Tube

Interventions: Drug: Enzalutamide

First Posted Date: 2013-11-03

Last Posted Date: 2023-04-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT01974765

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis

Completed

Conditions: Brain Cancer

Interventions: Procedure: MRI

First Posted Date: 2013-11-03

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01974804

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Dexmedetomidine
Drug: Placebo

First Posted Date: 2013-10-31

Last Posted Date: 2024-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 333

Registration Number: NCT01973452

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States

and more 1 locations

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Phase 2

Completed

Conditions: Esophageal Adenocarcinoma

Interventions: Device: MatriStem PSM

First Posted Date: 2013-10-28

Last Posted Date: 2023-11-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 78

Registration Number: NCT01970306

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Phase 1

Completed

Conditions: EGFR-Mutant Lung Cancer

Interventions: Drug: erlotinib

First Posted Date: 2013-10-22

Last Posted Date: 2018-11-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT01967095

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy